These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive and Nevro businesses and our ability to successfully integrate and ...

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 million. The repurchase includes the Audobon, Pennsylvania-based orthoped ...